Skip to content
Home/Companies/Biotech/Thabor Therapeutics
Thabor Therapeutics

Thabor Therapeutics

Biotech·France·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns Thabor Therapeutics?

Thabor Therapeutics is currently owned by AdBio Partners through AFB Fund II (2021 vintage), since 2021.

Hand-verified · updated 2026-04-21

AdBio Partners
Investor
AdBio Partners
AFB Fund II · 2021 · VC

Key facts

HQFrance
SectorBiotech
Websitewww.thabor-tx.com

More from AFB Fund II

Other portfolio companies in the same fund.

Orikine Bio
Active
BiotechSpain· 2026
AndzonBio2
AndzonBio2
Active
BiotechFrance· 2025
Cephagenix
Cephagenix
Active
BiotechDenmark· 2025
EvlaBio
Active
BiotechGermany· 2025
AndzonBio1
AndzonBio1
Active
BiotechFrance· 2024
Anoat Therapeutics
Active
BiotechFrance· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Thabor Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Thabor Therapeutics?

5 strategic and 115financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Thabor Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue